SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is in the spotlight as investors debate the potential long-term impact of a bipartisan Senate bill aimed at banning sports-based prediction markets, which could remove a significant competitive threat to traditional sportsbooks. While some in the community see this as a pivotal win that strengthens the company's regulatory moat, others remain deeply skeptical, pointing to persistent insider selling, ongoing lawsuits, and general frustration with the stock's inability to sustain upward momentum.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is facing intense backlash and investor frustration following a 1-for-12 reverse stock split that has left many shareholders deep in the red and questioning management's long-term strategy. The community is heavily focused on the company's lack of transparent communication, stagnant performance, and the perceived abandonment of retail investors in favor of Disney's controlling stake.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with concerns over the company's heavy AI capital expenditures, the uncertain ROI of OpenAI, and a broader rotation away from software stocks. The community is deeply divided, with many debating whether the current price represents a generational buying opportunity for a fundamental giant or if the stock is broken due to perceived leadership failures and a lack of clear AI monetization.

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund is experiencing extreme volatility and massive upside momentum as retail investors chase exposure to high-profile private AI and space firms like SpaceX and Anthropic. While the community is debating the disconnect between the fund's net asset value and its current trading premium, bullish sentiment remains fueled by the limited float due to share lockups and anticipation of upcoming IPOs.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing heightened investor attention following the upcoming departure of a key FDA official, which market participants view as a potential catalyst for a more predictable regulatory environment for rare disease gene therapies. The community remains heavily focused on the company's strong revenue base and upcoming clinical data readouts for its siRNA pipeline, with many investors actively debating the stock's valuation versus its growth potential.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention as investors position themselves for a potential SpaceX IPO, with the stock viewed by many as a unique vehicle to gain exposure to high-growth private tech giants like SpaceX, OpenAI, and Anthropic. Community discussion remains polarized, however, as some traders highlight the stock's potential for high volatility and a potential short squeeze due to its low float, while others express caution regarding its valuation relative to its Net Asset Value (NAV) and the risks of paying a premium for closed-end fund holdings.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently the center of intense market discussion following a strategic shift to sell its own in-house AGI CPU chips for data centers, which management expects will generate billions in annual revenue by 2031. Investors and analysts are actively debating the company's valuation and the potential for a massive rerating, as the move pivots Arm from a traditional IP licensing model to a direct silicon competitor in the AI-driven data center market.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant volatility following a regulatory setback, where the FDA issued a complete response letter regarding its drug candidate relacorilant for Cushing's syndrome due to requests for additional efficacy data. While the stock has faced intense selling pressure and scrutiny over the regulatory delay and ongoing patent litigation, the community is actively debating whether the sell-off is an overreaction given the company's established, profitable Korlym franchise and the upcoming pivotal data readouts for its oncology pipeline.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is facing intense volatility as investors debate the merit of a critical short report alleging aggressive accounting practices, while the company maintains its long-term growth narrative. The community remains deeply divided, with many long-term shareholders aggressively buying the dip on conviction that the allegations are unfounded, while others remain cautious due to management's muted initial response and the stock's significant price decline.

ORCASM is a filthy little memecoin that knows exactly what you came for. It launched on Orca's Wavebreak but was born to make waves—wet, loud, and unforgettable. This isn’t your ordinary meme. ORCASM builds up the tension slow, goes deep, and leaves you gasping for more. It’s raw, unfiltered trencher energy dripping with shameless satisfaction. No promises. No roadmaps. Just pure, orcasmic pleasure.

Orcasm

Investors are shifting focus from animal-themed meme coins toward sea-creature narratives, fueling community excitement around the low market capitalization potential of Orcasm. Discussions center on rallying collective momentum to establish the project as a market leader while coordinating cross-token support across the sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update

RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.

Down 27% in 4 Weeks, Here's Why Adma Biologics (ADMA) Looks Ripe for a Turnaround 

The heavy selling pressure might have exhausted for Adma Biologics (ADMA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

New Strong Buy Stocks for March 25th

EQT, BCBP, FIX, PAAS and ADMA have been added to the Zacks Rank #1 (Strong Buy) List on March 25, 2026.

ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.7% - What's Next?

ADMA Biologics (NASDAQ:ADMA) Shares Down 8.7% - Should You Sell...

<ul class="summary-bullets"><li>Without the sales figure inflation, Culper estimates Adma's revenues declined 3% in 2025 as compared to the 20% growth reported.&nbsp;</li><li>According to Culper, the growth story for the company’s flagship product Asceniv is already over and the shares of the company are now headed lower.</li><li>Culper alleged, based on its research, that the company induced its distributor to stock excess Asceniv by offering rebates and extended payment terms in order to meet order expectations.</li></ul> Shares of Adma Biologics Inc. (ADMA) closed 17% lower on Tuesday after Culper Research said it has taken a short position in the company.Culper alleged in a report that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor."Without the sales figure inflation, Culper estimates Adma's revenues declined 3% in 2025 as compared to the 20% growth reported.<h2 class="st-heading-2">Asceniv Sales And Demand</h2>According to Culper, the growth story for the company’s flagship product Asceniv is already over and the shares of the company are now headed lower. Asceniv is an FDA-approved intravenous immune globulin used for treating Primary Humoral Immunodeficiency (PI), a common inborn error of immunity characterized by reduced or dysfunctional antibody production.Culper alleged, based on its research, that the company induced its distributor to stock excess Asceniv by offering rebates and extended payment terms in order to meet order expectations. However, there isn’t as much demand, leaving distributors with excess inventory, the firm said.“Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there,” the firm alleged, while adding that it believes that the company’s reported Asceniv revenues are inflated by 40-76%. Culper also noted that company insiders, including CEO Adam Grossman, have collectively sold over $50 million in stock in the past 3 years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ADMA stock rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ADMA">ADMA stock</a> has dived 44% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-terafab-project-first-step-towards-tesla-spacex-merger-says-wedbush/cZ3nAP9RI10">Elon Musk’s Terafab Project First Step Towards Tesla-SpaceX Merger, Says Wedbush</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ADMA Biologics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ADMA Stock Drops 17% After Culper Research Alleges Channel Stuffing

Culper alleged that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor." 

Equity

Culper alleged that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor." 


LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and infrequent dosing boosting its promise.

ADMA Biologics (NASDAQ:ADMA) Sets New 52-Week Low  - Here's Why

ADMA Biologics (NASDAQ:ADMA) Hits New 52-Week Low - Should You Sell...

FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma

Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.

New Strong Buy Stocks for March 23rd

LCUT, EFXT, MGA, ADMA and JLL have been added to the Zacks Rank #1 (Strong Buy) List on March 23, 2026.

Traders are intensely debating the validity and credibility of allegations made by Culper Research regarding potential accounting irregularities.

Shareholders are calling on CEO Adam Grossman to issue a stronger, more transparent rebuttal to defend the firm's financial reputation.

Long-term investors see the current price weakness as a major discount and are aggressively adding to their positions.

Speculation is swirling that the company or institutional partners may be using the price dip to accelerate share repurchases.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.19	--	--	N/A
Q4 '25	$0.19	$0.21	15.22%	BEAT
Q3 '25	$0.15	$0.16	6.75%	BEAT
Q2 '25	$0.14	$0.15	7.78%	BEAT
Q1 '25	$0.15	$0.14	-11.21%	MISSED

ADMA
Adma Biologics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest ADMA News

ADMAAdma Biologics Inc